Publications by authors named "Kenneth C Sutton"

Claim this Profile
L
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study.
Kenneth C Sutton, Jerome De Vente, Roger Leblanc, Edwin Dejesus, Graham Smith

Open Forum Infect Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
Anthony Mills, Gary J Richmond, Cheryl Newman, Olayemi Osiyemi, Jerry Cade, Kenneth C Sutton

AIDS· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Graham H R Smith, W Keith Henry, Daniel Podzamczer, Maria Del Mar Masiá, Christopher J Bettacchi, Kenneth C Sutton

Open Forum Infect Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
David A Margolis, Juan Gonzalez-Garcia, Hans-Jürgen Stellbrink, Joseph J Eron, Yazdan Yazdanpanah, Kenneth C Sutton

Lancet· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis